Cancer Therapy: Preclinical

TGF-β Blockade Controls Ascites by Preventing Abnormalization of Lymphatic Vessels in Orthotopic Human Ovarian Carcinoma Models

Shan Liao1, Jieqiong Liu1,2, Peichun Lin1, Tony Shi3, Rakesh K. Jain1, and Lei Xu1

Abstract

Purpose: Ovarian cancer patients with malignant ascites have poor prognosis. The accumulation of ascites is caused by an imbalance between fluid extravasation from the blood vessels and reabsorption by lymphatic vessels. Whereas, the role of TGF-β in tumor progression has been well studied, the role of TGF-β in lymphatic vessel function is far from understood. Here, we sought to dissect the role of TGF-β blockade in the formation of ascites.

Experimental Design: We used soluble TGF-β Receptor II (sTβRII) to block TGF-β signaling in two orthotopic human ovarian carcinoma models: SKOV3ip1 and Hey-A8. We measured tumor proliferation, apoptosis, lymphangiogenesis, and angiogenesis by immunohistochemical staining, and examined diaphragm lymphatic vessel network by intraperitoneal injection of a fluorescent dye. Diaphragm lymphatic vessel function was assessed by tracking fluorescent beads in the diaphragm and measuring their drainage rate.

Results: TGF-β blockade impaired tumor growth in both models, accompanied by a decreased tumor cell proliferation and angiogenesis. More strikingly, TGF-β blockade almost completely abolished ascites formation. TGF-β blockade significantly inhibited the expression of VEGF, which is the major contributor to ascites formation. At the same time, TGF-β blockade prevent ‘abnormalization’ of diaphragm lymphatic vessels and improved ascites drainage.

Conclusions: TGF-β blockade decreased ascites by both inhibiting ascites formation and improving ascites drainage. Based on our finding, it is reasonable to consider the use of TGF-β blockade as a palliative treatment for symptomatic ascites.

Introduction

Ovarian cancer is characterized by rapid growth of peritoneal tumors and accumulation of ascites (1). When present in large amounts, ascites increases abdominal pressure and leads to pain, loss of appetite, nausea, and reduced mobility. In addition to tumor eradication, symptomatic relief from ascites becomes a primary therapeutic goal for many patients. Therapeutic options are limited to paracentesis and diuretics followed by peritoneovenous shunts, diet measures and other modalities like systemic or intraperitoneal chemotherapy (2). However, these treatments only temporally alleviate the symptoms and can induce adverse effects and discomfort.

In contrast to the treatment of underlying cancer, so far there is no generally accepted evidence-based guideline for the management of malignant ascites.

The ascites results from excessive production and impaired drainage of intraperitoneal fluid (3, 4). Vascular Endothelial Growth Factor/Vascular Permeability Factor (VEGF/VPF) is crucial for the production of malignant ascites (3). Avastin, a recombinant humanized monoclonal antibody to VEGF, has been shown to reduce ascites (5). However, it only inhibits the production of peritoneal fluid but does not affect ascites drainage. Lymphatic vessels in the diaphragm drain peritoneal fluid (6). We have previously shown that lymphatic vessels in hyperplastic, dysplastic, and neoplastic lesions are compressed and nonfunctional (7). Indeed, relieving the compressive mechanical stress opens up lymphatic vessels, however, these vessels still remain nonfunctional, presumably due to irreversible damage in the lymphatic valves (8, 9). We and others have been shown both preclinically and clinically that antiangiogenic therapy can “normalize” tumor blood vessels (10–12). However, there are no studies on how to normalize lymphatic vessels. Here, we show that TGF-β blockade inhibits ascites production (via inhibition of VEGF production) and prevents ‘abnormalization’ of lymphatic vessel function, resulting in almost complete...
Ovarian cancer is characterized by the rapid growth of solid intraperitoneal tumors and accumulation of ascites, the ascites being the clinical presentation of end-stage disease. Whereas the role of TGF-β in tumor angiogenesis and progression is well understood, its role in lymphatic vessel function remains far from understood. To this end, we dissected the potential role of TGF-β blockade in controlling ascites using human ovarian cancer xenografts in mice. We found that blocking tumor and host TGF-β signaling can significantly inhibit the growth of both VEGF- and interleukin-8–dependent human ovarian tumors. More importantly, we discovered that TGF-β blockade significantly decreases the volume of ascites by both inhibiting ascites formation and preventing impairment of lymphatic vessel drainage, thus demonstrating its potential as a promising new treatment for malignant ascites. Because a number of agents that target the TGF-β-pathway are in clinical trials, the results of the proposed study could be rapidly translated to the clinic.

### Methods

#### Cell lines

SKOV3ip1 and Hey-A8 cells were gifts from Dr. Isaiah J. Fidler (M.D. Anderson Cancer Center, Houston, TX). Mv1Lu cells were obtained from ATCC.

#### Plasmid construction

Mouse TGF-β receptor II extracellular domain was amplified from a mouse heart cDNA library and cloned into pKAV5CD5 vector, which contains a CD5 leader upstream of the human IgG1 hinge region sequences (a gift from Dr. Brian Seed, Center for Computational and Integrative Biology, Massachusetts General Hospital).

#### Purification and activity of the sTβRII

The sTβRII constructs were transfected into 293 cells by Lipofectamine 2000 (Invitrogen). Following overnight incubation, cells were washed with PBS and changed to fresh medium containing 0% FBS. After 3 days of incubation, the supernatant was collected and centrifuged; recombinant sTβRII was purified with Protein A Sepharose chromatography in accordance with manufacturer's protocol (Chemicon International). To determine the activity of sTβRII, serial dilutions of sTβRII was incubated for 1 hour with 0.1 ng/mL TGF-β1, 0.5 ng/mL TGF-β2, and 0.05 µg/mL TGF-β3 (R&D Systems), and then added to Mv1Lu cells (13). Cell proliferation was determined by [3H]Thymidine incorporation assay (14).

#### Orthotopic implantation

SKOV3ip1 and Hey-A8 tumor cells were injected i.p. into female nude mice (1 x 10^6 cells/mice). Intraperitoneal injection of tumor cells produced solid tumors grown on the surface of the peritoneal organs and tumors invaded into the diaphragm. Mice bearing SKOV3ip1 tumors also produced large amount of ascites. Mice were sacrificed 35 days later. Peritoneal tumors were excised and weighed. Malignant ascites were aspirated and measured (14).

#### Northern blot analysis

Northern blot was performed as described previously (15). cDNA probes were synthesized by PCR, using the following primers: interleukin (IL)-8F: 5'-CGG ACA GAC AGA CAG ACA CC-3'; IL-8R: 5'-AAG AAA ACT GGG TGC AGA G-3'. VEGF-F: 5'-AAG GAG GAG GGC AGA ATC AT-3'; VEGF-R: 5'-AAA AAC GAA AGC GCA AGA AA-3'.

#### ELISA

Tumor tissue was lysed to extract protein, and IL-8 and VEGF were quantified using Quantikine ELISA kit (R&D Systems). IL-8 and VEGF levels (pg/mL) were normalized by the amount of total protein measured using DC Protein Assay (Bio-Rad; mg/mL; ref. 16).

#### Western blot analysis

Cells or tumor tissue was lysed to extract protein (16). A total of 30 µg of protein per sample was separated on SDS-polyacrylamide gels (17). Phosphorylation status of SMAD was detected by phospho-specific antibodies (Cell Signaling, Danvers, MA).

### Immunohistochemistry

Tissue sections (5-µm-thick) of formalin-fixed, paraffin-embedded tumor xenografts were deparaffinized in xylene and rehydrated in graded alcohol. The endogenous peroxidase was blocked with the addition of 3% hydrogen peroxide in PBS for 12 minutes. The samples were incubated for 20 minutes at room temperature with protein-blocking solution [PBS (pH 7.5) containing 5% normal horse serum and 1% normal goat serum] followed by incubation at 4°C with primary antibodies (anti-CD31, 1:800; BD Biosciences; anti-Proliferating Cell Nuclear Antigen (PCNA), 1:50; Dako Corporation; F4/80, 1:10; Serotec, Raleigh; LYVE-1 and α-SMA). The samples were then rinsed and incubated for 1 hour at room temperature with a peroxidase-conjugated anti-rabbit IgG. The slides were rinsed with PBS and incubated for 5 minutes with diaminobenzidine. The sections were then washed 3 times with distilled water, counterstained with Mayer's hematoxylin, washed once with distilled water and once more with PBS. The slides were mounted with a universal mount and examined with a bright-field microscope (18).
Terminal deoxynucleotidyl transferase–mediated
dUTP nick end labeling

For terminal deoxynucleotidyl transferase–mediated
dUTP nick end labeling (TUNEL) staining, tissue samples were fixed in 4% (w/v) paraformaldehyde in phosphate-buffered saline. Paraffin-embedded sections (5 μm) were used for in situ detection of apoptotic cells. After deparaffinization and rehydration, tissue sections were stained with terminal deoxynucleotidyl transferase and incubated with diaminobenzidine. The sections were counterstained with Methyl Green, and the percentage of TUNEL-positive cells was quantified (Millipore; ref. 19).

Functional assays for lymphatic vessel drainage

Four weeks after cell implantation, mice were injected i.p. with fluorescent beads (0.2 mL, 1 μm in diameter). Two hours later, diaphragms were harvested and fixed with 4% paraformaldehyde for fluorescent microscopy. Claudal mediastinal lymph nodes (CMLN) were harvested and homogenized to measure fluorescence intensity with fluorescent plate reader (Perkin Elmer).

Diphtheria toxin treatment

When SKOV3ip1 tumor-bearing mice developed visible ascites, diphtheria toxin (1 mg) or PBS was injected i.p. (8). Five days later, mice were sacrificed to test lymphatic function.

Data analysis and interpretation

All data are presented as mean ± SD. The significance of differences between 2 groups was analyzed using the Student’s t test (2-tailed) or Mann–Whitney U test (2-tailed).

Characterization of sTβRII

We used 2 methods to block tumor and host TGF-β signaling. First we stably transfected the sTβRII construct into SKOV3ip1 and Hey-A8 cells. These transfected cells constitutively secreted large quantities of sTβRII protein (Fig. 1A and B). Second, we used purified recombinant sTβRII protein as a therapeutic agent. To test the function of the purified sTβRII protein, we treated Mv1Lu cells with recombinant TGF-β1, -β2, and -β3 in the presence or absence of purified sTβRII. Our purified sTβRII successfully blocked TGF-β1 and -β3 but not TGF-β2–mediated inhibition of cell proliferation (data not shown). It also blocked TGF-β1 induced phosphorylation of Smad2 (Fig. 1C).

Blocking tumor and host TGF-β signaling inhibits ovarian cancer growth and ascites formation

In the first group, we orthotopically implanted parental, mock- and sTβRII-transfected SKOV3ip1 (SKOV-sTβRII) and Hey-A8 (Hey-sTβRII) cells i.p. into nude mice. We examined peritoneal tumor weight at day 35. Transfection of sTβRII decreased tumor weight in both models (P < 0.01). Mice implanted with SKOV3ip1 and mock-transfected cells formed large amounts of bloody ascites, whereas transfection of sTβRII almost completely abolished ascites formation (Fig. 2A and B).

In the second group, we implanted parental SKOV3ip1 and Hey-A8 cells i.p. into nude mice. Seven days after
tumor implantation, we began treatment with control IgG or recombinant sTβRII protein (1 mg/kg, i.p., every 3 days). Recombinant sTβRII treatment significantly inhibited tumor growth (P < 0.01). More dramatically, sTβRII treatment almost completely abolished ascites formation (Fig. 2C and D, P < 0.001).

**Blocking tumor and host TGF-β signaling inhibits tumor cell proliferation and angiogenesis via inhibition of IL-8 and VEGF expression**

VEGF and IL-8 are angiogenic and autocrine growth factors for ovarian tumors (20). In TGF-β-blocked tumors, VEGF and IL-8 mRNA and protein decreased significantly (Fig. 3A and B). As a result, we found the number of PCNA+ cells decreased significantly in TGF-β blocked tumors (SKOV3-sTβRII: 36 ± 13; Hey-sTβRII: 62 ± 27) compared with parental tumors (SKOV3ip1: 128 ± 25; Hey-A8: 142 ± 22; data shown as number of PCNA+ cells per 0.329 mm2 area; P < 0.001). We also found parental tumors had significantly more CD31+ endothelial cells (SKOV3ip1: 62 ± 7; Hey-A8: 48 ± 4) than sTβRII tumors (SKOV3-sTβRII: 22 ± 4; Hey-sTβRII: 16 ± 6; Fig. 3C) (P<0.001, data are shown as number of CD31+ structures per 1.355 mm2).

Tumor-associated macrophages (TAM) play an important role in tumor progression (6). We examined the effect of TGF-β blockade on TAM infiltration in peritoneal ovarian tumors using the macrophage marker F4/80. A lower infiltrating macrophage density was detected in SKOV3-sTβRII tumors (52 ± 16) than in SKOV3ip1 tumors (145 ± 22, P < 0.001, data are shown as number of F4/80+ cells per 1.335 mm2).

**Blocking tumor and host TGF-β signaling prevented abnormalization of diaphragm lymphatic vessel network**

We examined the diaphragm lymphatics by fluorescence lymphangiography (FITC-dextran, 0.2 mL, 2×106 MW, i.p.). Twenty minutes later, diaphragms were collected and observed under fluorescence microscopy. In nontumor-bearng mice, we observed the distinct outline of organized lymphatic strips on the peritoneal side of the diaphragm. In mice bearing SKOV3ip1 tumors, the diaphragms contained lymphatic vessels of increased density.
and branching. In SKOV-sTβRII tumor-bearing mice, lymphatic strips appeared similar to those in normal mice. On the pleural side of the diaphragms, the dye showed normal lymphatic network in nontumor-bearing mice, an enlarged arrangement of lymphatic vessels in mice bearing SKOV3ip1 tumors and a "normalized" lymphatic network in mice with SKOV-sTβRII tumors (Fig. 4A). Quantification data showed TGF-β blockade decreased diameter of lymphatic vessels on the pleural side (Fig. 4B).

Normal lymphatic vessels have 1-way valves to prevent fluid from flowing backwards (21). We visualized lymphatic valves using CD31 and LYVE-1 double staining in whole mounts of the diaphragm. In parental tumors, profound lymphangiogenesis occurred and lymphatic valve structures disappeared completely—similar to our previous observations (9). In contrast, in TGF-β blocked tumors, normal lymphatic network was present and valve structures remained intact (Fig. 4C).

Blocking tumor and host TGF-β signaling decreased diaphragm lymphangiogenesis

In peritoneal tumors attached to the surface of peritoneal organs, we found little LYVE-1 immunostaining (data not shown). However, in tumors invading the diaphragms, LYVE-1 immunostaining showed that lymphatic vessels were abundant, enlarged and irregularly shaped. In diaphragms with invading SKOV-sTβRII tumors, lymphatic vessel density (in size-matched tumors in the diaphragm) had decreased (Fig. 5).

We further analyzed the number of infiltrating macrophages in (size-matched) tumors invading the diaphragm. In diaphragms from nontumor-bearing mice, using staining with CD11b (an alternative marker for macrophages), we found no infiltrating macrophages. In mice with SKOV3ip1 tumors, we identified a high number of macrophages (these cells being closely associated with LYVE-1–positive lymphatic vessels; Fig. 5). In diaphragms with invading tumors...
SKOV-sTβRII tumor, we identified the same amount of positive CD11b staining, but a reduced number of LYVE-1–positive vessels. This observation indicates that despite the presence of a large number of macrophage, these cells still require the presence of TGF-β to induce lymphangiogenesis.

Blocking tumor and host TGF-β signaling improved lymphatic vessel function

To study whether TGF-β blockade affects the function of diaphragm lymphatic vessels, we injected fluorescent beads intraperitoneally. In nontumor-bearing mice, few beads were observed in the diaphragm 2 hours after injection, indicating their clearance through the lymphatic vessels. In SKOV3ip1 tumor-bearing mice, despite the large number of lymphatic vessels, many beads remained in the diaphragm, indicating impaired drainage. In SKOV-sTβRII tumor-bearing mice, few beads were present (Fig. 6A).

Diaphragm lymphatic vessels drain into the CMLN. To confirm and quantify drainage, we measured fluorescence intensity of beads drained to CMLN. Compared with mice with normal drainage, CMLNs from SKOV3ip1 tumor-bearing mice had low fluorescence intensity, indicating decreased drainage. CMLNs from SKOV-sTβRII tumor-bearing mice showed high fluorescence intensity (Fig. 6B), indicating TGF-β blockade improved drainage to CMLN.

This functional normalization may be attributed to TGF-β decreasing tumor weight, thus relieving the compression of lymphatic vessels (8). Indeed, we observed that in mice treated with diphtheria toxin (DT), which is much less cytotoxic to mouse than to human cells, ascites were resolved to a similar extent as in sTβRII-treated mice (Control group: 3.5 ± 1.7 mL, DT group: 0.1 ± 0.3 mL).

Discussion

TGF-β is a multifunctional cytokine. Depending on the context, it can act on the tumor cells to increase epithelial to mesenchymal transition (EMT), migration, invasion, and survival. It can act on stromal cells to induce angiogenesis and dampen local immune surveillance (22–24).
Recent studies also showed TGF-β to affect intratumoral distribution of chemotherapeutic agents (25, 26). We chose to study TGF-β because both TGF-β and its receptors are overexpressed in ovarian carcinomas, and because genes in the TGF-β signaling pathway are dysregulated in ovarian carcinomas (27). Several strategies to block TGF-β are being tested in various stages of investigation, from the laboratory to phase III clinical trials (28). These strategies fall into 2 categories: direct inhibition of TGF-β (via TGF-β neutralizing antibodies, soluble TGF-β receptors and decorin) and interference with the downstream signaling cascades (e.g., interferon-γ, peroxisome proliferator activated receptor-γ agonist). Soluble TGF-β receptor II competes with cell-bound TβRII for active TGF-β ligand, resulting in reduced TGF-β signaling. We chose to use this strategy because it has been shown that TGF-β1 and -β3 play a greater role in ovarian cancer progression than TGF-β2 (29), and sTβRII has been shown to specifically block the effects of TGF-β1 and -β3 (26).

In our study, we utilized a well-established human ovarian carcinoma orthotopic model in nude mice. When human ovarian cancer cells were injected orthotopically (intraperitoneal) into nude mice, they produced solid tumors that invaded the surface of peritoneal organs and diaphragm, and these tumors formed ascites. This growth pattern mimics the growth of human ovarian cancer in patients. We used 2 methods to block tumor and host TGF-β signaling. First, we established sTβRII-overproducing ovarian tumor cells (genetic approach). Second, we treated tumor-bearing mice with recombinant sTβRII (pharmacologic approach). A previous study showed that 5 days after tumor cell i.p. injection, diaphragmatic lymph vessels become occluded (30, 31). In our study, we also observed small tumors established on the diaphragm and in the peritoneal cavity 7 days after tumor implantation. This tumor burden mimics that in patients after cytoreductive surgery and adjuvant chemotherapy. Based on these published studies and our own observations, we started sTβRII treatment 7 days after tumor implantation, when tumor lesions and obstruction of lymphatics were established.

Targeted therapy often fails because different tumors depend on different growth/angiogenic factors for their progression. The outcome of a therapy using specific inhibitors depends on the expression level of the target in the tumor, which varies significantly between patients. In addition, malignant tumors often switch growth factor dependence, thus permitting ‘therapeutic escape’ from specific, targeted drugs (15). In our study, we used 2 human ovarian carcinoma cell lines to represent cancer heterogeneity. SKOV3ip1 cells express high levels of VEGF and low levels of IL-8. When implanted orthotopically into the peritoneal cavity of nude mice, these cells formed solid tumors with large volumes of ascites. On the other hand, Hey-A8 cells express high levels of IL-8 and low levels of VEGF. When implanted orthotopically into the peritoneal cavity of nude mice, these cells formed solid tumors with little ascites (32). Previous study using PTK787, a VEGFR2 tyrosine kinase inhibitor, to block VEGF pathways has shown that inhibition of VEGF was only effective in inhibiting the growth of VEGF-dependent tumors.
SKOV3ip1 tumors but not IL-8–dependent Hey-A8 tumors (14). TGF-β stands at the crossroad of diverse signaling pathways, therefore, targeting TGF-β would have the advantage of bypassing the 2 problems—pointed out previously—associated with VEGF- or IL-8–targeted therapies. Indeed, in our study, we observed that TGF-β blockade inhibited the expression of both VEGF and IL-8. As a result, TGF-β blockade effectively inhibited the progression of both VEGF-dependent (SKOV3ip1) and IL-8–dependent (Hey-A8) human ovarian tumor xenografts.

Increased fluid production and decreased lymphatic absorption are identified as contributing factors of ascites formation. In our study, we administered sTβRII intraperitoneally and showed a dual effect on ascites production and drainage. Tumors exhibit extensive angiogenesis, but tumor blood vessels are structurally and functionally abnormal (11). These vascular abnormalities contribute to high vessel permeability. Decreasing permeability of tumor vessels by inhibiting VEGF signaling using VEGF trap (soluble decoy receptor) or a VEGF neutralizing antibody has been shown to inhibit the formation of malignant ascites (33–35). TGF-β blockade has been shown to recruit pericyte and induce blood vessel “normalization” (26); this, combined with our data showing TGF-β blockade inhibits VEGF production, provides a mechanism for decreased ascites production.

Furthermore, we studied the effect of TGF-β blockade on ascites drainage by examining vessel morphology and function of diaphragm lymphatics. The function of TGF-β on tumor growth and progression has been studied extensively (36), however, its effect on lymphangiogenesis was only recently studied (6, 37, 38). Therefore, its effect and underlying mechanisms on lymphatic vessel function remain largely unknown. Recent studies showed TGF-β can directly block lymphatic regeneration (in wound healing) and signal transduction in lymphatic endothelial cells (37, 38). TGF-β can also increase the secretion of lymphangiogenic factors, thus indirectly enhancing lymphangiogenesis (6). The net result depends on the balance of the response to TGF-β. In our study, we observed that peritoneal ovarian tumors induced profound lymphangiogenesis in the diaphragm. However, these newly formed lymphatic vessels are not functional. Based on previous studies, which
showed diaphragmatic lymph vessels becoming occluded 5 days after intraperitoneal injection of tumor cells (30, 31), we administered i.p. sTGFbRII 7 days after tumor implantation. We showed TGF-β blockade decreased lymphangiogenesis, reduced tumor burden in the diaphragm and maintained the normal lymphatic vessel morphology and valve structure. As a result, it improved the drainage function of diaphragm lymphatic vessels. This dual effect of TGF-β blockade on ascites production and drainage explains why it is a more efficient strategy than blocking VEGF alone (e.g., treatment with PTK787 leads to a 50% decrease in ascites volume, whereas sTGFbRII decreased ascites volume by 98%; ref. 39).

In summary, our study shows that by blocking tumor and host TGF-β signaling we can significantly inhibit the growth of both VEGF- and IL-8–dependent human ovarian tumors. More importantly, we have shown that TGF-β blockade significantly decreases the volume of ascites by both inhibiting ascites formation and preventing impairment of lymphatic vessel drainage, thus demonstrating its potential as a new treatment for malignant ascites.

References


TGF-β Blockade Controls Ascites by Preventing Abnormalization of Lymphatic Vessels in Orthotopic Human Ovarian Carcinoma Models

Shan Liao, Jieqiong Liu, Peichun Lin, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-10-2429

Cited articles
This article cites 39 articles, 15 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/17/6/1415.full#ref-list-1

Citing articles
This article has been cited by 9 HighWire-hosted articles. Access the articles at:
http://clincancerres.aacrjournals.org/content/17/6/1415.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.